

# Jorge R Georgakopoulos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9584465/publications.pdf>

Version: 2024-02-01

38  
papers

511  
citations

687363

13  
h-index

713466

21  
g-index

38  
all docs

38  
docs citations

38  
times ranked

643  
citing authors

#	ARTICLE	IF	CITATIONS
1	Facial and neck erythema associated with dupilumab treatment: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1339-1347.	1.2	63
2	Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 155-157.	1.2	42
3	Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 1019-1020.	1.2	37
4	Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e32-e34.	2.4	27
5	Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 801-803.	1.2	27
6	A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 623-626.	1.2	25
7	Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1530-1532.	1.2	23
8	Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 290-296.	1.2	21
9	Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e7-e8.	2.4	20
10	Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1212-1214.	1.2	19
11	Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 174-177.	1.2	18
12	Short- and Long-Term Management of an Acute Pustular Psoriasis Flare: A Case Report. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 452-456.	1.2	14
13	Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series. <i>JAAD Case Reports</i> , 2018, 4, 310-313.	0.8	14
14	Long-term dupilumab treatment for chronic refractory generalized prurigo nodularis: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1049-1051.	1.2	14
15	Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 591-601.	1.2	13
16	Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 422-423.	1.2	12
17	Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: A real-world Canadian multicenter retrospective study. <i>JAAD International</i> , 2021, 4, 67-69.	2.2	12
18	Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, 26, 319-320.	1.2	12

#	ARTICLE	IF	CITATIONS
19	A case of rituximab-induced pyoderma gangrenosum. JAAD Case Reports, 2018, 4, 979-981.	0.8	11
20	Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study. Journal of the American Academy of Dermatology, 2018, 79, 953-956.	1.2	10
21	Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis. Journal of Cutaneous Medicine and Surgery, 2019, 23, 391-393.	1.2	10
22	Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 400-410.	0.8	9
23	Prevalence and Characteristics of Dupilumab-Induced Ocular Surface Disease in Adults With Atopic Dermatitis. Cornea, 2022, 41, 1242-1247.	1.7	8
24	Rate of Patient-Driven Biologic Treatment Discontinuation During the COVID-19 Pandemic in 2 Academic Hospital Clinics at the University of Toronto. Journal of Cutaneous Medicine and Surgery, 2020, 24, 424-425.	1.2	7
25	Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	7
26	Incidence of Conjunctivitis and Other Ocular Surface Disorders in Patients With Long-Term Dupilumab Use. Journal of Cutaneous Medicine and Surgery, 2020, 24, 527-528.	1.2	7
27	Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e416-e418.	2.4	6
28	Incidence and prognosis of COVID-19 in psoriasis patients on biologic therapy: a multicentre retrospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e485-e487.	2.4	6
29	Long-term 52-week trends in apremilast safety outcomes for treatment of psoriasis in clinical practice: a multicentre, retrospective case series. British Journal of Dermatology, 2019, 180, 211-212.	1.5	3
30	Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice. Journal of Cutaneous Medicine and Surgery, 2020, 24, 418-419.	1.2	3
31	A systematic review of vitiligo onset and exacerbation in patients receiving biologic therapy. JAAD International, 2021, 2, 37-39.	2.2	3
32	Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis: A Canadian Multicenter Retrospective Cohort Study. Journal of Cutaneous Medicine and Surgery, 2020, 24, 468-473.	1.2	3
33	Efficacy and Safety of Adalimumab and Infliximab for Noninfectious Uveitis. Ophthalmology, 2022, 129, 357-359.	5.2	3
34	The Utility of IL-17 Inhibitors in Neutrophilic Dermatoses: A Systematic Review. Journal of Cutaneous Medicine and Surgery, 2021, , 120347542110453.	1.2	1
35	A Systematic Review Characterizing Psoriatic Arthritis Onset and Exacerbation in Patients Receiving Biologic Therapy. Journal of Cutaneous Medicine and Surgery, 2022, , 120347542210885.	1.2	1
36	Patient-Centred Care When Treating Plaque Psoriasis With Secukinumab: Reasons for Discontinuing Treatment Outside of Randomized Controlled Trials. Journal of Cutaneous Medicine and Surgery, 2018, 22, 647-649.	1.2	0

#	ARTICLE	IF	CITATIONS
37	Impact of COVID-19 on Patient-Initiated Discontinuation of Omalizumab in Two Academic Hospital Clinics at the University of Toronto. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 534-535.	1.2	0
38	AB0939 Off-label secukinumab dose escalation in the treatment of moderate-to-severe psoriasis: a multicenter, retrospective study. , 2018, , .		0